Not provided
Not provided
Not provided
Not provided
The study was inactive and no continuing review was submitted, resulting in its expiration and termination
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary hyperhidrosis is a pathological condition characterized by the idiopathic and excessive secretion of sweat beyond normal physiological demand and is localized at particular foci such as the face, axilla, palms of the hands, and soles of the feet. Patients seeking medical attention for hyperhidrosis often report disruptions to their professional and/or social lives due to sweating and subsequently experience many psychosocial difficulties, such as anxiety, social phobia, and depression. Therefore, a psychiatric explanation of causality is frequently offered for these patients during diagnosis. Excessive sweating is often mistakenly interpreted as a symptom of an anxiety disorder and can be cause for social embarrassment, exacerbating emotional stress and social avoidance. As currently constituted, the treatment of secondary psychosocial symptoms in primary hyperhidrosis is poorly understood and requires further investigation.
Primary Objective:
To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis.
Secondary Objectives:
To characterize the outcomes of and clinical response to the MiraDry ® treatment system with respect to the aforementioned criteria.
To compare the results of non-invasive miraDry ® treatment system to the existing surgical correction with respect to the aforementioned criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MiraDry ® treatment | Experimental | MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface. Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MiraDry ® | Device | Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface |
|
| Measure | Description | Time Frame |
|---|---|---|
| Disease Severity as Assessed by the Hyperhidrosis Disease Severity Scale (HDSS) | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Hyperhidrosis Disease Severity Scale (HDSS). HDSS assigns a point value where severity is scored: Minimal (1)=My sweating is never noticeable and never interferes with my daily activities to most severe score is: (4)=My sweating is intolerable and always interferes with my daily activities. Lower point values are considered better and higher point values are considered worse. | Baseline, 6 months, 1 Year |
| Quality of Life as Assessed by the Dermatology Quality of Life Index | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Dermatology Quality of Life Index. Total score range from 0-30, a higher score indicating more impairment on the participant's quality of life | Baseline, 6 months, 1 Year |
| Social Phobia as Assessed by the Social Phobia Inventory (SPIN) | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Social Phobia Inventory (SPIN) consisting of 17 questions to assess social phobia. The lowest possible score is 0 and the highest is 68. A score of 19 or more on the SPIN suggests social phobia or social anxiety disorder. A lower score, or reduction in score, is better. | Baseline, 6 months, 1 Year |
| Anxiety as Assessed by the Zung Self-rating Anxiety Scale (ASL) | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Zung Self-rating Anxiety Scale (ASL). The score range is 20-80: 20-44 Normal Range, 45-59 Mild to Moderate Anxiety Levels, 60-74 Marked to Severe Anxiety Levels, 75-80 Extreme Anxiety Levels. |
Not provided
Not provided
Inclusion Criteria:
This study will recruit patients diagnosed with focal hyperhidrosis with a known diagnosis of primarily axillary localization.
We will only enroll patients available for both treatment visits. Availability for follow-up visit is optional.
Only patients between the ages of 18 and 29 years when the first HHIQ is administered will be eligible.
The upper age limit was so determined because patients over 29 years often present with psychopathology which is far more recalcitrant to correction of any kind regardless of effectiveness because of the duration of the condition.
The lower age limit was so determined because 18 years and up are the ages for which the miraDry ® procedure has been approved for use by the FDA.
All participants will be screened using the Hyperhidrosis Disease Severity Scale (HDSS).
Only patients reporting their condition as a 3 out of 4 or higher on the HDSS will be eligible for study because preliminary data suggests effective detection of psychological changes only at higher reported levels of sweating severity.
A patient's previous non-invasive treatment course, including but not limited to prescription of psychiatric medication and topical therapies, will not justify exclusion from this study.
Exclusion Criteria:
Patients who are unable to provide informed consent, have known allergies to lidocaine, hibiclens with 4% chlorhexidine, and/or epinephrine, are pregnant (as determined by self-reporting), are unable to take oral antibiotics or antiseptic washes, have heart pacemakers or other electronic device implants, and who need supplemental oxygen are not eligible to participate in this study
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Malcolm Brock, MD | Johns Hopkins University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins University | Baltimore | Maryland | 21287 | United States |
Total 31 patients signed consents-
Participants who have focal hyperhidrosis with a known diagnosis of primarily axillary localization were recruited from both the Johns Hopkins Department of Dermatology and Thoracic Surgery. The recruitment of these patients will occur during normal appointments and clinic visits at Johns Hopkins Hospital.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | MiraDry ® Treatment Group | MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface. Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Data collected for participants who had at least 1 psychological evaluation and 1 MiraDry treatment appointment
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | MiraDry ® Treatment Group | MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface. Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Disease Severity as Assessed by the Hyperhidrosis Disease Severity Scale (HDSS) | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Hyperhidrosis Disease Severity Scale (HDSS). HDSS assigns a point value where severity is scored: Minimal (1)=My sweating is never noticeable and never interferes with my daily activities to most severe score is: (4)=My sweating is intolerable and always interferes with my daily activities. Lower point values are considered better and higher point values are considered worse. | Participants with data collected are reported | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months, 1 Year |
|
Up to 24 months.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | MiraDry ® Treatment Group | Patients who suffer from psychosocial symptoms related to axillary hyperhidrosis. Each patient is required to undergo 2 MiraDry treatments, 3 months apart. The patients are also required to complete 4 surveys at the initial appointment, and the same 4 again at follow up. |
Not provided
Not provided
Some patients had issues with the cost of the third round of treatments, if necessary. Sometimes the study team needed to reach out a few times in order to get all questionnaires completed.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Kristen Rodgers- Research Program Manager, Dept, of Thoracic Surgery | Johns Hopkins University | 410-955-9047 | kpelosk1@jhmi.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 21, 2014 | Apr 2, 2025 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Oct 7, 2014 | Apr 2, 2025 | ICF_001.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, 6 months, 1 Year |
| Functioning as Assessed by the Achenbach Self Report (ASR) | To evaluate the effectiveness of the MiraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Achenbach Self Report, with a score range of 0 to 240, with score of 65 being marked as concerning. A lower score correlates to better functioning. | Baseline, 6 months, 1 Year |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| hyperhidrosis in primarily axillary localization | Count of Participants | Participants |
|
|
|
| Primary | Quality of Life as Assessed by the Dermatology Quality of Life Index | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Dermatology Quality of Life Index. Total score range from 0-30, a higher score indicating more impairment on the participant's quality of life | Participants with data collected are reported | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months, 1 Year |
|
|
|
| Primary | Social Phobia as Assessed by the Social Phobia Inventory (SPIN) | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Social Phobia Inventory (SPIN) consisting of 17 questions to assess social phobia. The lowest possible score is 0 and the highest is 68. A score of 19 or more on the SPIN suggests social phobia or social anxiety disorder. A lower score, or reduction in score, is better. | Participants with data collected are reported. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months, 1 Year |
|
|
|
| Primary | Anxiety as Assessed by the Zung Self-rating Anxiety Scale (ASL) | To evaluate the effectiveness of the miraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Zung Self-rating Anxiety Scale (ASL). The score range is 20-80: 20-44 Normal Range, 45-59 Mild to Moderate Anxiety Levels, 60-74 Marked to Severe Anxiety Levels, 75-80 Extreme Anxiety Levels. | Participants with data collected are reported | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months, 1 Year |
|
|
|
| Primary | Functioning as Assessed by the Achenbach Self Report (ASR) | To evaluate the effectiveness of the MiraDry ® treatment system for psychosocial functioning in patients heavily affected by axillary hyperhidrosis. Patients will be asked to complete the Achenbach Self Report, with a score range of 0 to 240, with score of 65 being marked as concerning. A lower score correlates to better functioning. | Participants with data collected are reported | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months, 1 Year |
|
|
|
| 0 |
| 24 |
| 0 |
| 24 |
| 0 |
| 24 |
Not provided
Not provided
|
| 1 year |
|
|
|
| 1 year |
|
|
|
| 1 year |
|
|
|
| 1 year |
|
|